PureTech Health Reports Strong Portfolio Financing Progress
In its 2026 half-year results call, PureTech Health highlighted significant progress across its portfolio companies. The company reported $220 million in cash and short-term investments at the parent level, with an operational runway expected to last through at least the end of 2028. Seaport Therapeutics raised $260 million via a Nasdaq IPO, while Celea Therapeutics secured $180 million for its global Phase III trial of deupirfenidone in idiopathic pulmonary fibrosis. Gallop Oncology received FDA Fast Track designation for LYT-200 and plans to begin a 125-patient Phase II trial once external financing is secured. CEO Robert Lyne emphasized PureTech's strategy shift toward earlier external funding, aiming to improve capital efficiency while retaining equity stakes and potential milestones or royalties in its founded entities. PureTech also noted that it has generated over $1 billion from the Karuna Therapeutics/Cobenfy partnership for schizophrenia treatment. The company expects future annual cash burn of approximately $30–$40 million, a significant reduction compared to previous years.
Topics: biotech capital efficiency clinical trials portfolio financing